CoChat

Early SRC activation skews cell fate from apoptosis to senescence

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Cells responding to DNA damage implement complex adaptive programs that often culminate in one of two distinct outcomes: apoptosis or senescence. To systematically identify factors driving each response, we analyzed human IMR-90 fibroblasts exposed to increasing doses of the genotoxin etoposide and identified SRC as a key kinase contributing early to this dichotomous decision. SRC was activated by low but not high levels of etoposide. With low DNA damage, SRC-mediated activation of p38 critically promoted expression of cell survival and senescence proteins, while SRC-mediated repression of p53 prevented a rise in proapoptotic proteins. With high DNA damage, failure to activate SRC led to elevation of p53, inhibition of p38, and apoptosis. In mice exposed to DNA damage, pharmacologic inhibition of SRC prevented the accumulation of senescent cells in tissues. We propose that inhibiting SRC could be exploited to favor apoptosis over senescence in tissues to improve health outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.abm0756

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Prosurvival signaling in senescence-committed cells implicates active SRC. (A and B) Strategy (A) and timeline (B) to assess the threshold of etoposide (Etop) triggering IMR-90 cell senescence or apoptosis. (C) Percent live cells, assessed by direct cell counts, following etoposide treatment as in (B); green arrow, time selected for subsequent analyses. (D) SA-β-Gal staining 10 days after no treatment or 50 μM etoposide. Scale bar, 100 μm. Right, percent SA-β-Gal–positive cells. (E and F) BrdU incorporation (E) and RT-qPCR analyses of p16 and IL6 mRNA levels, normalized to ACTB mRNA levels (F), in cells processed as in (B). (G) STRING analysis of proteins differentially phosphorylated 48 hours after 50 or 200 μM etoposide treatments; graph, number of protein interactions for each protein indicated. (H) Heatmap representation of protein sites with significantly changed phosphorylation after 50 and 200 μM etoposide treatment (n = 2 per condition). Arrow, SRC(Y419) phosphorylation. (I) Western blot analysis of the indicated proteins; ACTB, loading control. (J) Western blot analysis of SRC levels (top) and RT-qPCR analysis SRC mRNA levels (bottom) in IMR-90 fibroblasts treated as shown. (K) IMR-90 fibroblasts were transfected with siCtrl or siSRC, treated as indicated, and live cells were counted 48 hours later. (L to N) Forty-eight hours after siRNA transfections, cells were treated with caspase inhibitor Z-VAD-FMK and 50 μM etoposide; 48 hours later, the remaining cells were counted (L) and caspase 3/7–dependent activity was assessed (M); cell viability and caspase 3/7 activity without etoposide exposure (N). (O to S) Constitutively active SRC(CA) and dominant-negative SRC(DN) lentiviral constructs (O) were transduced and induced by doxycycline (1 μg/ml) in IMR-90 cells treated with 200 or 50 μM etoposide (P) or proliferating (Q); cell viability was assessed as in (C). Western blot analysis of myc-tagged SRC mutants after 72 hours in doxycycline (R and S). Data in (C) to (F), (J) to (N), (P), and (Q) are means ± SD (n = 3 experiments); significance (*P < 0.05, **P < 0.01, ***P < 0.001) using two-tailed Student’s t test. ns, not significant.
Fig. 1. Prosurvival signaling in senescence-committed cells implicates active SRC. (A and B) Strategy (A) and timeline (B) to assess the threshold of etoposide (Etop) triggering IMR-90 cell senescence or apoptosis. (C) Percent live cells, assessed by direct cell counts, following etoposide treatment as in (B); green arrow, time selected for subsequent analyses. (D) SA-β-Gal staining 10 days after no treatment or 50 μM etoposide. Scale bar, 100 μm. Right, percent SA-β-Gal–positive cells. (E and F) BrdU incorporation (E) and RT-qPCR analyses of p16 and IL6 mRNA levels, normalized to ACTB mRNA levels (F), in cells processed as in (B). (G) STRING analysis of proteins differentially phosphorylated 48 hours after 50 or 200 μM etoposide treatments; graph, number of protein interactions for each protein indicated. (H) Heatmap representation of protein sites with significantly changed phosphorylation after 50 and 200 μM etoposide treatment (n = 2 per condition). Arrow, SRC(Y419) phosphorylation. (I) Western blot analysis of the indicated proteins; ACTB, loading control. (J) Western blot analysis of SRC levels (top) and RT-qPCR analysis SRC mRNA levels (bottom) in IMR-90 fibroblasts treated as shown. (K) IMR-90 fibroblasts were transfected with siCtrl or siSRC, treated as indicated, and live cells were counted 48 hours later. (L to N) Forty-eight hours after siRNA transfections, cells were treated with caspase inhibitor Z-VAD-FMK and 50 μM etoposide; 48 hours later, the remaining cells were counted (L) and caspase 3/7–dependent activity was assessed (M); cell viability and caspase 3/7 activity without etoposide exposure (N). (O to S) Constitutively active SRC(CA) and dominant-negative SRC(DN) lentiviral constructs (O) were transduced and induced by doxycycline (1 μg/ml) in IMR-90 cells treated with 200 or 50 μM etoposide (P) or proliferating (Q); cell viability was assessed as in (C). Western blot analysis of myc-tagged SRC mutants after 72 hours in doxycycline (R and S). Data in (C) to (F), (J) to (N), (P), and (Q) are means ± SD (n = 3 experiments); significance (*P < 0.05, **P < 0.01, ***P < 0.001) using two-tailed Student’s t test. ns, not significant.CC BY-NC · PubMed Central
Fig. 2. Inhibition of the SRC activity orients cells toward apoptosis instead of senescence. (A) Schedule of SRC inhibitor and etoposide treatments. (B and C) IMR-90 cell viability was measured by direct cell counting 48 hours after treatment with SRC inhibitors and 50 μM etoposide (B) or no etoposide (C). Dashed line, cells present at t = 0 (C). (D) Representative IMR-90 cell micrographs 48 hours after treatment with 50 μM etoposide and SRC inhibitors. Scale bars, 100 μm. (E to G) Cell viability, measured as in (B), 48 hours after treating IMR-90 cells with doxorubicin (Doxo) (250 nM) and SRC inhibitors (E); senescence was assessed by SA-β-Gal staining (F) and BrdU incorporation (G) assays. (H to J) IMR-90 cell viability 48 hours after treatment with IR (10 Gy) and SRC inhibitors (H). Senescence was assessed by SA-β-Gal staining (I) and BrdU incorporation (J) assays. (K to N) Percent live human WI-38 fibroblasts (direct counts) after treatment with different etoposide concentrations (K); senescence at day 10 was assessed by SA-β-Gal staining (L), BrdU incorporation (M), and RT-qPCR analysis of the levels of p16 and IL6 mRNAs, normalized to ACTB mRNA levels (N). (O and P) Viability (direct counts) of WI-38 fibroblasts treated with 50 μM etoposide (O) or untreated (P) and treated with SRC inhibitors; dashed line, cell numbers at t = 0. (Q to T) Percent live human BJ fibroblasts (direct counts) after treatment with different etoposide concentrations (Q); senescence at day 10 was assessed by SA-β-Gal staining (R), BrdU incorporation (S), and RT-qPCR analysis of the levels of p16 and IL6 mRNAs, normalized to ACTB mRNA levels (T). (U and V) Viability (direct counts) of BJ fibroblasts treated with 50 μM etoposide (U) or untreated (V) and treated with SRC inhibitors; dashed line, cell numbers at t = 0. In (B), (C), and (E) to (V), significance was assessed by two-tailed Student’s t test. Graphs represent means ± SD (n = 3 experiments); significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined using two-tailed Student’s t test.
Fig. 2. Inhibition of the SRC activity orients cells toward apoptosis instead of senescence. (A) Schedule of SRC inhibitor and etoposide treatments. (B and C) IMR-90 cell viability was measured by direct cell counting 48 hours after treatment with SRC inhibitors and 50 μM etoposide (B) or no etoposide (C). Dashed line, cells present at t = 0 (C). (D) Representative IMR-90 cell micrographs 48 hours after treatment with 50 μM etoposide and SRC inhibitors. Scale bars, 100 μm. (E to G) Cell viability, measured as in (B), 48 hours after treating IMR-90 cells with doxorubicin (Doxo) (250 nM) and SRC inhibitors (E); senescence was assessed by SA-β-Gal staining (F) and BrdU incorporation (G) assays. (H to J) IMR-90 cell viability 48 hours after treatment with IR (10 Gy) and SRC inhibitors (H). Senescence was assessed by SA-β-Gal staining (I) and BrdU incorporation (J) assays. (K to N) Percent live human WI-38 fibroblasts (direct counts) after treatment with different etoposide concentrations (K); senescence at day 10 was assessed by SA-β-Gal staining (L), BrdU incorporation (M), and RT-qPCR analysis of the levels of p16 and IL6 mRNAs, normalized to ACTB mRNA levels (N). (O and P) Viability (direct counts) of WI-38 fibroblasts treated with 50 μM etoposide (O) or untreated (P) and treated with SRC inhibitors; dashed line, cell numbers at t = 0. (Q to T) Percent live human BJ fibroblasts (direct counts) after treatment with different etoposide concentrations (Q); senescence at day 10 was assessed by SA-β-Gal staining (R), BrdU incorporation (S), and RT-qPCR analysis of the levels of p16 and IL6 mRNAs, normalized to ACTB mRNA levels (T). (U and V) Viability (direct counts) of BJ fibroblasts treated with 50 μM etoposide (U) or untreated (V) and treated with SRC inhibitors; dashed line, cell numbers at t = 0. In (B), (C), and (E) to (V), significance was assessed by two-tailed Student’s t test. Graphs represent means ± SD (n = 3 experiments); significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined using two-tailed Student’s t test.CC BY-NC · PubMed Central
Fig. 3. Essential factors for cell fate determination are regulated by signaling through SRC. (A and B) GSEA plots (A) and heatmap (B) depicting microarray analysis of mRNAs encoding proapoptotic (A) or prosurvival (B) proteins in untreated or etoposide-treated IMR-90 fibroblasts; data in (B) are row z score of log2-normalized transcript values (n = 3). (C) Validation of the top microarray targets PUMA, PMAIP1, BCL2L2, and BCL2L1 mRNAs by RT-qPCR analysis (see also fig. S2A). (D) Western blot analysis of proteins expressed in cells treated as in (A) to (C). (E) Viability (direct counts) of cells transfected with the siRNAs shown, then treated with 200 μM etoposide (left) or left untreated (right). Significant differences are indicated above (siPUMA versus siCtrl) and below (siPMAIP1 versus siCtrl) the curves. (F) Viability (direct counts) of cells that were transfected with the siRNAs shown, either treated with 50 μM etoposide (left) or left untreated (right). Significant differences are indicated above (siBCL2L1 versus siCtrl) and below (siBCL2L2 versus siCtrl) the curves. (G) Viability (direct counts) of cells transfected with the siRNAs shown, then treated with 50 μM etoposide (left) or left untreated (right). (H) RT-qPCR analysis of PUMA and BCL2L2 mRNAs (normalized to ACTB mRNA) after etoposide treatment for different times. (I) Western blot analysis of the proteins shown; means ± SD from densitometric quantification of phosphorylated SRC(Y419) (n = 3) is shown. (J) Enrichr analysis of terms (columns, hub proteins) and input proteins (rows); filled cells designate row proteins associated with hub proteins (Materials and Methods). (K) Heatmap representation (top) of quantified densitometry signals from p53 by Western blot analysis (bottom) in IMR-90 cells treated as indicated. (L and M) Heatmap representation (L) of the quantified densitometry signals on Western blots (M) detecting phosphorylated protein relative to corresponding total protein. Data represent log2 of the normalized values. Graphs (C) and (E) to (I) represent means ± SD (n = 3 experiments); significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined using two-tailed Student’s t test.
Fig. 3. Essential factors for cell fate determination are regulated by signaling through SRC. (A and B) GSEA plots (A) and heatmap (B) depicting microarray analysis of mRNAs encoding proapoptotic (A) or prosurvival (B) proteins in untreated or etoposide-treated IMR-90 fibroblasts; data in (B) are row z score of log2-normalized transcript values (n = 3). (C) Validation of the top microarray targets PUMA, PMAIP1, BCL2L2, and BCL2L1 mRNAs by RT-qPCR analysis (see also fig. S2A). (D) Western blot analysis of proteins expressed in cells treated as in (A) to (C). (E) Viability (direct counts) of cells transfected with the siRNAs shown, then treated with 200 μM etoposide (left) or left untreated (right). Significant differences are indicated above (siPUMA versus siCtrl) and below (siPMAIP1 versus siCtrl) the curves. (F) Viability (direct counts) of cells that were transfected with the siRNAs shown, either treated with 50 μM etoposide (left) or left untreated (right). Significant differences are indicated above (siBCL2L1 versus siCtrl) and below (siBCL2L2 versus siCtrl) the curves. (G) Viability (direct counts) of cells transfected with the siRNAs shown, then treated with 50 μM etoposide (left) or left untreated (right). (H) RT-qPCR analysis of PUMA and BCL2L2 mRNAs (normalized to ACTB mRNA) after etoposide treatment for different times. (I) Western blot analysis of the proteins shown; means ± SD from densitometric quantification of phosphorylated SRC(Y419) (n = 3) is shown. (J) Enrichr analysis of terms (columns, hub proteins) and input proteins (rows); filled cells designate row proteins associated with hub proteins (Materials and Methods). (K) Heatmap representation (top) of quantified densitometry signals from p53 by Western blot analysis (bottom) in IMR-90 cells treated as indicated. (L and M) Heatmap representation (L) of the quantified densitometry signals on Western blots (M) detecting phosphorylated protein relative to corresponding total protein. Data represent log2 of the normalized values. Graphs (C) and (E) to (I) represent means ± SD (n = 3 experiments); significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined using two-tailed Student’s t test.CC BY-NC · PubMed Central
Fig. 4. SRC-mediated p53 repression and p38 activation promotes prosurvival responses in early senescence. (A) Heatmap representation of p53 levels (top) quantified by densitometry from signals on Western blots (bottom, representative panel) in IMR-90 cells transfected with siCtrl or siSRC siRNAs, either untreated or treated with 50 μM etoposide for 48 hours. (B) Heatmap representation of densitometry quantification of signals on Western blots detecting phosphorylated residues, normalized to protein levels assessed in cells transfected with siCtrl or siSRC siRNAs that were either left untreated or treated with 50 μM etoposide for 48 hours. (C) Representative Western blot analysis of the data shown in (B). (D) Quantification of PUMA, PMAIP1, BCL2L2, and BCL2L1 mRNAs by RT-qPCR analysis. Data were normalized to the levels of ACTB mRNA. (E) Representative Western blot analysis of the levels of PUMA and BCL2L2 proteins. (F) Levels of phosphorylated SRC (Y419), total SRC, myc tag, phospho-p38 (T180/Y182), p38, and p53 in the different conditions tested. The levels of ACTB were assessed to evaluate loading differences. Values indicate means ± SD from signals obtained in three independent experiments. (G) Quantification of PUMA and BCL2L2 mRNAs by RT-qPCR analysis; data were normalized to the levels of ACTB mRNA. (H) Representative Western blot analysis of the levels of proteins expressed from the transcripts in (F). (I) Cell viability was assessed in IMR-90 fibroblasts treated with 50 μM etoposide and either left without further treatment or treated with PP1 or PP2 for 48 hours or 10 days. (J) The levels of PUMA and BCL2L2 mRNAs were quantified by RT-qPCR analysis in cells treated with 50 μM etoposide for the times shown; data were normalized to the levels of ACTB mRNA. Values shown in (D), (G), (I), and (J) are means ± SD; significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined using two-tailed Student’s t test.
Fig. 4. SRC-mediated p53 repression and p38 activation promotes prosurvival responses in early senescence. (A) Heatmap representation of p53 levels (top) quantified by densitometry from signals on Western blots (bottom, representative panel) in IMR-90 cells transfected with siCtrl or siSRC siRNAs, either untreated or treated with 50 μM etoposide for 48 hours. (B) Heatmap representation of densitometry quantification of signals on Western blots detecting phosphorylated residues, normalized to protein levels assessed in cells transfected with siCtrl or siSRC siRNAs that were either left untreated or treated with 50 μM etoposide for 48 hours. (C) Representative Western blot analysis of the data shown in (B). (D) Quantification of PUMA, PMAIP1, BCL2L2, and BCL2L1 mRNAs by RT-qPCR analysis. Data were normalized to the levels of ACTB mRNA. (E) Representative Western blot analysis of the levels of PUMA and BCL2L2 proteins. (F) Levels of phosphorylated SRC (Y419), total SRC, myc tag, phospho-p38 (T180/Y182), p38, and p53 in the different conditions tested. The levels of ACTB were assessed to evaluate loading differences. Values indicate means ± SD from signals obtained in three independent experiments. (G) Quantification of PUMA and BCL2L2 mRNAs by RT-qPCR analysis; data were normalized to the levels of ACTB mRNA. (H) Representative Western blot analysis of the levels of proteins expressed from the transcripts in (F). (I) Cell viability was assessed in IMR-90 fibroblasts treated with 50 μM etoposide and either left without further treatment or treated with PP1 or PP2 for 48 hours or 10 days. (J) The levels of PUMA and BCL2L2 mRNAs were quantified by RT-qPCR analysis in cells treated with 50 μM etoposide for the times shown; data were normalized to the levels of ACTB mRNA. Values shown in (D), (G), (I), and (J) are means ± SD; significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined using two-tailed Student’s t test.CC BY-NC · PubMed Central
Fig. 5. SRC-FAK activation influences cell viability by signaling through p38 and p53. (A) Viable IMR-90 cells (direct counts) following 48 hours of treatment with etoposide (50 μM) plus p38i (AL 8697, 10 μM), p53a (Nutlin-3a, 10 μM), p53a + p38i, PP1 (5 μM), or PP2 (5 μM); see also fig. S3B. (B) RT-qPCR analysis of PUMA and BCL2L2 mRNAs (normalized to ACTB mRNA) in cells treated as in (A). (C) Western blot analysis of the proteins shown (and loading control ACTB). (D) Cell viability (direct counting) after 48-hour treatment as indicated; doxycycline-induced SRC(CA) expression was performed as in Fig. 1R simultaneously with the other treatments. (E) RT-qPCR analysis of PUMA and BCL2L2 mRNAs (normalized to ACTB mRNA) in cells treated as in (D). (F) Analysis of proteins preferentially phosphorylated at 50 μM etoposide ranked CAS-SRC-FAK at the top using CORUM database and Enrichr analysis using data from Fig. 1H. (G) Western blot analysis of p-FAK (activating phosphorylation Y576/Y577), FAK, and loading control ACTB. (H and I) Viability (direct counting) of cells transfected with the siRNAs shown and treated with etoposide (H), and Western blot analysis (I) of the proteins shown (p-p38 is phosphorylated at T180/Y182). (J and K) GSEA (J) and heatmap (K) analyses of the levels of mRNAs encoding EMT and integrin proteins (z scores of the log2-normalized expression values, n = 3). (L and M) GSEA of relevant gene sets in the conditions indicated after expressing SRC(DN) (see also fig. S3E) (L) or SRC(CA) (M). (N) Proposed model (created using BioRender). Senescence-causing, low-level DNA damage (lower half) activates SRC, decreasing p53 function and activating p38 (lowering PUMA, elevating BCL2L2). Apoptosis-causing, high-level DNA damage (top half) does not activate SRC and instead activates p53 and represses p38, in turn increasing PUMA and lowering BCL2L2 levels and leading to apoptosis. Values shown in (A), (B), (D), (E), and (H) are means ± SD (n ≥ 3); significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined by using two-tailed Student’s t test.
Fig. 5. SRC-FAK activation influences cell viability by signaling through p38 and p53. (A) Viable IMR-90 cells (direct counts) following 48 hours of treatment with etoposide (50 μM) plus p38i (AL 8697, 10 μM), p53a (Nutlin-3a, 10 μM), p53a + p38i, PP1 (5 μM), or PP2 (5 μM); see also fig. S3B. (B) RT-qPCR analysis of PUMA and BCL2L2 mRNAs (normalized to ACTB mRNA) in cells treated as in (A). (C) Western blot analysis of the proteins shown (and loading control ACTB). (D) Cell viability (direct counting) after 48-hour treatment as indicated; doxycycline-induced SRC(CA) expression was performed as in Fig. 1R simultaneously with the other treatments. (E) RT-qPCR analysis of PUMA and BCL2L2 mRNAs (normalized to ACTB mRNA) in cells treated as in (D). (F) Analysis of proteins preferentially phosphorylated at 50 μM etoposide ranked CAS-SRC-FAK at the top using CORUM database and Enrichr analysis using data from Fig. 1H. (G) Western blot analysis of p-FAK (activating phosphorylation Y576/Y577), FAK, and loading control ACTB. (H and I) Viability (direct counting) of cells transfected with the siRNAs shown and treated with etoposide (H), and Western blot analysis (I) of the proteins shown (p-p38 is phosphorylated at T180/Y182). (J and K) GSEA (J) and heatmap (K) analyses of the levels of mRNAs encoding EMT and integrin proteins (z scores of the log2-normalized expression values, n = 3). (L and M) GSEA of relevant gene sets in the conditions indicated after expressing SRC(DN) (see also fig. S3E) (L) or SRC(CA) (M). (N) Proposed model (created using BioRender). Senescence-causing, low-level DNA damage (lower half) activates SRC, decreasing p53 function and activating p38 (lowering PUMA, elevating BCL2L2). Apoptosis-causing, high-level DNA damage (top half) does not activate SRC and instead activates p53 and represses p38, in turn increasing PUMA and lowering BCL2L2 levels and leading to apoptosis. Values shown in (A), (B), (D), (E), and (H) are means ± SD (n ≥ 3); significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined by using two-tailed Student’s t test.CC BY-NC · PubMed Central
Fig. 6. SRC inhibition prevents accumulation of senescent cells in doxorubicin-induced senescence in mice. (A) Overview of the schedule of experiments performed in mice. (B) Measurement of the levels of p21 and Il6 mRNAs by RT-qPCR analysis in lungs treated as in (A); data were normalized to Actb mRNA levels. (C) Representative micrographs of p21 immunofluorescent staining of the experimental groups indicated. Scale bar, 50 μm. (D) Quantification of p21-positive cells in each tissue assayed; see also fig. S4 (A and B). (E) Percentages of TUNEL-positive cells in lungs from the indicated experimental groups. See also fig. S4C. Graph in (B) shows the mean values ± SD of n = 3 independent experiments. Graphs in (B), (D), and (E) display the means (bars) and each individual value as a dot ± SD of n = 6 mice; significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined using two-tailed Student’s t test.
Fig. 6. SRC inhibition prevents accumulation of senescent cells in doxorubicin-induced senescence in mice. (A) Overview of the schedule of experiments performed in mice. (B) Measurement of the levels of p21 and Il6 mRNAs by RT-qPCR analysis in lungs treated as in (A); data were normalized to Actb mRNA levels. (C) Representative micrographs of p21 immunofluorescent staining of the experimental groups indicated. Scale bar, 50 μm. (D) Quantification of p21-positive cells in each tissue assayed; see also fig. S4 (A and B). (E) Percentages of TUNEL-positive cells in lungs from the indicated experimental groups. See also fig. S4C. Graph in (B) shows the mean values ± SD of n = 3 independent experiments. Graphs in (B), (D), and (E) display the means (bars) and each individual value as a dot ± SD of n = 6 mice; significance (*P < 0.05, **P < 0.01, ***P < 0.001) was determined using two-tailed Student’s t test.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 73

Metadata

Authors
Anerillas, C., Herman, A. B., Rossi, M., Munk, R., Lehrmann, E., Martindale, J. L., Cui, C.-Y., Abdelmohsen, K., De, S., & Gorospe, M.
Affiliations
National Institute on Aging (US)
Corresponding author
  • Anerillas, Carlos
  • Gorospe, Myriam
Venue
Science Advances
Published
2022-04-08
Volume
8
Issue
14
Pages
eabm0756-eabm0756
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4223486770
Cited by
71
References
63
Citations by year
2026: 19 · 2025: 15 · 2024: 18 · 2023: 14 · 2022: 5
FWCI
8.05
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (1z01ag000511-08, Z01-AG000511)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
Src kinase, DNA damage response, cellular senescence, apoptosis, p38 MAPK, p53, etoposide, IMR-90 fibroblasts, Src kinase inhibition
MeSH terms
Animals, DNA Damage, Etoposide, Fibroblasts, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, src-Family Kinases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.